Skip to main content

GNE-9815 (C09-1134-775)

Aladdin

Catalog No.
C09-1134-775
Manufacturer No.
G646439-10mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $577.08
List Price: $641.20

GNE-9815 (compound 7) is a highly selective, pan- RAF inhibitor with good oral bioavailability. GNE-9815 exhibits K i values of 0.062 and 0.19 nM for CRAF and BRAF , respectively. GNE-9815 combines with MEK inhibitor Cobimetinib ( HY-13064 ) shows

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
GNE-9815 (compound 7) is a highly selective, pan- RAF inhibitor with good oral bioavailability. GNE-9815 exhibits K i values of 0.062 and 0.19 nM for CRAF and BRAF , respectively. GNE-9815 combines with MEK inhibitor Cobimetinib ( HY-13064 ) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancersIn VitroGNE-9815 shows synergistic activity in KRAS mutant A549 and HCT116 cancer cells in combination with the MEK inhibitor Cobimetinib. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoGNE-9815 (15 mg/kg; p.o.; single) demonstrates synergistic MAPK pathway modulation when combines with the MEK inhibitor Cobimetinib in an HCT116 xenograft mouse model . GNE-9815 (5 mg/kg; p.o.; single) shows good oral bioavailability and (1 mg/kg; i.v.; single) exhibits low blood clearance, moderate volume of distribution, and short half-life . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NCR nude mice (6 to 8-week-old; 24-26 g; HCT116 xenograft mice model) . Dosage: 15 mg/kg Administration: Intravenous injection or oral administration; single. Result: Resulted in pathway inhibition as demonstrated by partial inhibition of pRSK between 2 and 24 h, but more robust, albeit transient, inhibition of the downstream MAPK target genes, DUSP6 and SPRY4. Led to deeper inhibition of the downstream MAPK target genes DUSP6 and SPRY4, when combined with the MEK inhibitor Cobimetinib, with maximal inhibition at 8 h and with a more modest rebound in levels at 24 h, post final dose. Animal Model: Female NCR nude mice (6 to 8-week-old; 24-26 g) . Dosage: 1 mg/kg (for i.v.); 5 mg/kg (for p.o.). Administration: Intravenous injection or oral administration; single. Result: Exhibited CL b , V dss and t 1/2 values of 17 mL/min∙kg, 1.7 L/kg and 1.9 h, respectively. Showed good oral bioavailability with F% of 37%. (methylcellulose/Tween formulation).Form:SolidIC50& Target:CRAF 0.062 nM (Ki) Braf 0.19 nM (Ki). Specification: 0.98 Molecular Formula: C26H22FN5O2 Molecular Weight: 455.48
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
G646439-10mg
CAS:
2729996-45-4
Product Size:
10mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.